Revista espanola de medicina nuclear e imagen molecular · 2025
In-depth clinical and dosimetric analysis of 166Ho-radioembolization in patients with liver cancer: An observational study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sá E Silva R, André Oliveira J, Santos J, Albergueiro R, Pereira P, Costa L
Аннотация
INTRODUCTION: Transarterial radioembolization (TARE) using holmium-166 (¹⁶⁶Ho) microspheres is a treatment for unresectable primary and secondary liver malignancies. The pre-therapeutic simulation procedure using a scout dose is critical to predict microsphere distribution and exclude extrahepatic leakage. This single-center observational study aimed to evaluate the dosimetric agreement between ¹⁶⁶Ho-scout and ¹⁶⁶Ho-therapy, and to correlate tumor-absorbed dose with treatment response at both tumor and patient levels.
METHODS: Prospective, observational study included patients with BCLC 2022 stage A/B hepatocellular carcinoma or oligometastatic liver disease undergoing ¹⁶⁶Ho-TARE were included. Voxel-based dosimetry was performed using Q-suite. Contrast-enhanced CT was acquired 3 months post-treatment. Treatment response was assessed by RECIST/mRECIST criteria.
RESULTS: Twenty patients underwent the pre-treatment procedure; 18 proceeded to therapy. No significant differences were observed between scout and therapy procedures in whole-liver (P=.331) and tumor doses (P=.063), indicating reliable pre-therapeutic evaluation. Fourteen patients with 16 treated lesions were included in the dose-response analysis (median volume: 22,1 [10,5-80,3]mL; dose: 22,1 [10,5-80,3]Gy). The objective tumor response rate at 3 months was 94%. However, no significant differences were found in absorbed dose metrics (P=.315) or dose-volume histogram values (D50, D70, D85) between responsive and non-responsive (NR) lesions. Patient-level analysis showed a 29% progression rate, with NR patients more likely to have secondary liver tumors (P=.011).
CONCLUSION: This study including a Portuguese cohort treated with ¹⁶⁶Ho-TARE showed a high tumor response rate. However, the limited sample size reduces the robustness of the conclusions. Further data from ongoing follow-up are awaited.
METHODS: Prospective, observational study included patients with BCLC 2022 stage A/B hepatocellular carcinoma or oligometastatic liver disease undergoing ¹⁶⁶Ho-TARE were included. Voxel-based dosimetry was performed using Q-suite. Contrast-enhanced CT was acquired 3 months post-treatment. Treatment response was assessed by RECIST/mRECIST criteria.
RESULTS: Twenty patients underwent the pre-treatment procedure; 18 proceeded to therapy. No significant differences were observed between scout and therapy procedures in whole-liver (P=.331) and tumor doses (P=.063), indicating reliable pre-therapeutic evaluation. Fourteen patients with 16 treated lesions were included in the dose-response analysis (median volume: 22,1 [10,5-80,3]mL; dose: 22,1 [10,5-80,3]Gy). The objective tumor response rate at 3 months was 94%. However, no significant differences were found in absorbed dose metrics (P=.315) or dose-volume histogram values (D50, D70, D85) between responsive and non-responsive (NR) lesions. Patient-level analysis showed a 29% progression rate, with NR patients more likely to have secondary liver tumors (P=.011).
CONCLUSION: This study including a Portuguese cohort treated with ¹⁶⁶Ho-TARE showed a high tumor response rate. However, the limited sample size reduces the robustness of the conclusions. Further data from ongoing follow-up are awaited.